GSK/Genmab's ofatumumab succeeds in first pivotal leukaemia trial
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlineand Genmabhave just announced that the pivotal, single-arm, single-agent Phase III trial of their experimental monoclonal antibody drug ofatumumab (HuMax-CD20) met its primary response endpoint at interim analysis in refractory chronic lymphocytic leukaemia (CLL).